GGrantIndex
← Search

GENE TRANSFER and SOMATIC CELL ENGINEERING

$206,277P30FY2012CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications, trials & patents

Trial NCT03699631Trial NCT02595918Trial NCT02417701Trial NCT02219737Trial NCT02152995Trial NCT01979523Trial NCT01947023Trial NCT01902160Trial NCT01705340Trial NCT01643278Trial NCT01638546Trial NCT01587352Trial NCT01585805Trial NCT01326702Trial NCT01281865Trial NCT01196416Trial NCT01154452Trial NCT01143402Trial NCT01119599Trial NCT01051557Trial NCT01026623Trial NCT01016015Trial NCT00957905Trial NCT00866177Trial NCT00729157Trial NCT00639509Trial NCT00601692Trial NCT00589472Trial NCT00570401Trial NCT00567229Trial NCT00550628Trial NCT00541034Trial NCT00528450Trial NCT00522301Trial NCT00521014Trial NCT00519974Trial NCT00514254Trial NCT00498927Trial NCT00483678Trial NCT00474994Trial NCT00471679Trial NCT00471601Trial NCT00470574Trial NCT00470470Trial NCT00462982Trial NCT00462501Trial NCT00459875Trial NCT00458705Trial NCT00453310Trial NCT00450827Trial NCT00416351Trial NCT00404365Trial NCT00398138Trial NCT00397904Trial NCT00369174Trial NCT00354679Trial NCT00334893Trial NCT00324480Trial NCT00245102Trial NCT00104845Trial NCT00090337Trial NCT00089245Trial NCT00087009Trial NCT00072345Trial NCT00072319Trial NCT00070057Trial NCT00067015Trial NCT00062374Trial NCT00059891Trial NCT00058253Trial NCT00054132Trial NCT00046917Trial NCT00040898Trial NCT00040872Trial NCT00039286Trial NCT00037011Trial NCT00036933Trial NCT00028730Trial NCT00024258Trial NCT00023764Trial NCT00020891Trial NCT00016146Trial NCT00014534Trial NCT00014469Trial NCT00008294Trial NCT00008242Trial NCT00006044Trial NCT00004245Trial NCT00004066Trial NCT00003923Trial NCT00003819Trial NCT00003173Trial NCT00003023Trial NCT00002981Trial NCT00002930Trial NCT00002766Trial NCT00002738Trial NCT00002718Trial NCT00002663Trial NCT00002558

Abstract

The Gene Transfer and Somatic Cell Engineering Core (GTS) supports the preclinical translation and clinical implementation of gene transfer studies at MSKCC. The supported projects are highly dependent on achieving efficient gene transfer in primary cells, including hematopoietic progenitor cells, T lymphocytes and dendritic cells. In the upcoming grant cycle, the GTS will mainly focus on the development and optimization of clinical cell engineering processes and on the implementation of clinical trials. The specific aims of the GTS are to carry out and/or coordinate: 1. Expansion and transduction of patient cells in semi-closed systems in collaboration with the investigators for clinical trials utilizing genetically modified cells; 2. Generation and characterization of high-titer producer cell clones, master cell banks (MCB) for clinical studies; 3. Production and titration of 5 to 15 liter batches of clinical viral stocks in semi-closed systems; 4. Production and biosafety testing of clinical grade plasmid DMA vaccine for immunization; 5. Detection of replication-competent retrovirus and other biosafety testing in cultured packaging cell clones (MCB), viral stocks and clinical specimen 6. Detection of oncoretroviral vector integration sites by LM-PCR in patient cells; 7. Cell banking, storage of viral stocks, plasmid DMA vaccine and clinical specimens. In addition, the GTS provides essential advisory and training functions for the generation of research grade reagents at the Center. Investigators are thus advised or trained on 1. How to optimize the transduction of various cell types; 2. How to construct recombinant gamma-retroviral and lentiviral vectors, plasmid DMA vectors, and shRNA encoding retroviral vectors; 3. What packaging cell lines to use; 4. How to transfect vector DMA in packaging cells and select producer cell lines; 5. What tests to perform to analyze gene expression; 6. How to titrate cell-free retroviral stocks by flow cytometry, Southern blot or real time PCR analysis. The GTS is thus a repository for numerous reagents and protocols that are made available to investigators at MSKCC. The centralization of cell transduction, vector production and plasmid DMA manufacturing in the GTS decreases the cost of clinical development, ensures high quality and consistency of molecular and cellular processes, and their availability to all investigators at the Center.

View original record on NIH RePORTER →